Navigation Links
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
Date:2/12/2009

el the global Otsuka organization to become a top tier global pharmaceutical company."

In his role as President and CEO of OAPI, Altmeyer will oversee all aspects of the company's operations. Altmeyer's appointment became effective on January 5, 2009, and he will operate out of OAPI's offices in both Rockville, Md., and Princeton, N.J.

"Having worked closely with Otsuka during the past decade, I understand the company's deep commitment to providing the health care community with innovative products, and I am honored to have the chance to lead this dynamic organization at such a significant time in the company's history," said Altmeyer. "Working with our sister companies in the Otsuka Pharmaceutical Group, I look forward to the opportunity to achieve our companies' mission of developing new products for better health worldwide."

Altmeyer earned his Bachelors of Arts from Middlebury College in Vermont, and his Masters in Business Administration from Harvard Graduate School of Business. He is on the Board of Directors for Contact of Mercer County and Trinity Counseling Service.

About Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative, fast-growing healthcare company that commercializes Otsuka-discovered and other product opportunities in North America, with a strong focus on and commitment to neuroscience, cardiovascular, oncologic, and gastrointestinal therapeutic treatments. OAPI is dedicated to improving patients' health and the quality of human life. OAPI is part of the Otsuka Pharmaceutical Group, and was established in 1989 by Otsuka America, Inc. (OAI), which is wholly owned by Otsuka Pharmaceutical Co., Ltd. (OPC). For additional information, please visit www.otsuka-us.com

About Otsuka Pharmaceutical Co., Ltd. (OPC)'/>"/>

SOURCE Otsuka America Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
2. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
3. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
4. Many Older Americans Have Active Sex Lives
5. Despite grumbling, most Americans say they are happy at work
6. Record Number of Americans Lack Health Insurance
7. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
8. Campaign for Americas Future Memorandum: Katrina Storm Warning
9. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
10. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
11. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... 27, 2015 Royal River Natural Foods, a ... new study that found adults who got the most magnesium ... diabetes compared to those who got the least magnesium, with ... , The report is part of the March 2015 issue ... River Natural Foods publishes free each month for the Freeport ...
(Date:2/27/2015)... Dr. Andrew Campbell, one of the ... to announce the expansion of Quintessa Aesthetic Center with ... has begun seeing patients on February 18, 2015. , ... offer a variety of state-of-the-art surgical and non-surgical ... laser peels, chemical peels, microdermabrasion, ProFractional Laser, Broad Band ...
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
Breaking Medicine News(10 mins):Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... at Wake Forest University School of Medicine reveals that many ... immediate medical needs of a student or employee who suffers ... to support a new statewide program to place automated external ... to appear in the May/June 2009 issue of the ...
... (SIS) unveils SIS Trax, a tissue management solution that ... for hospitals to standardize their processes for acquiring, receiving, ... solution to be fully integrated with a perioperative information ... enables hospitals to improve patient safety, optimize revenue, reduce ...
... Conference Vice President for Public Policy Paul A. ... executive order to be issued by President Obama ... cell research:"President Obama,s executive order regrettably places ideology ... advancements. There are endless studies and stories ...
... Connectivity to be Presented at HIMSS09LOS ANGELES, ... (OTC Bulletin Board: FVRL), which through its ... provides Web-based consumer-controlled Personal Health Records ("PHRs") ... box storage solutions ( www.myesafedepositbox.com ), announced ...
... Chef Cat Cora ( www.catcoracooks.com ), ... Chef of Bon Appetit is excited to announce she ... her first pregnancy and the fourth child for the Cora family. ... deliver their third child, also a boy, in April. "Jennifer and ...
... Seen in Patient Delays and Unnecessary StaysCOLLEGE PARK, Md., March ... Maryland,s Robert H. Smith School of Business put a ... hospitals at $12 billion per year. The research, newly released ... is the first to quantify the economic impact of a ...
Cached Medicine News:Health News:Study prompts new mandate for N.C. high schools 2Health News:Study prompts new mandate for N.C. high schools 3Health News:SIS Trax Unveiled as First Fully Integrated Tissue Management Solution 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 3Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 4Health News:Celebrity Chef Cat Cora Announces First Pregnancy 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 3
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... 27, 2015  Acsis Inc., the market leader for ... today that John DiPalo , Acsis, Chief Strategy ... Demand Chain Executive 2015 Provider Pro to Know. ... initiatives to help prepare their companies, and customers, supply ... This year,s list of Provider Pros to Know is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... (DSMB) Authorizes Enrollment of Cervical ... Authorized Dosage Level, HOPKINTON, Mass., Sept. 24 ... independent Data,Safety Monitoring Board (DSMB) has unanimously authorized expanding ... injury (SCI) to,allow subjects with cervical SCI to be ...
... Enrollment Ahead of Schedule with Completion Expected Q2 ... Inc. (Nasdaq: ALTH ) today announced the ... safety data from the,Company,s pivotal Phase 2 PROPEL ... refractory peripheral T-cell lymphoma (PTCL). Results of,the interim ...
Cached Medicine Technology:Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 2Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 3Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 4Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 5Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 7mm from end. Two .15mm ports 2mm, ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 21G x 7/8in (.80 ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
For injecting anesthetics into the muscle cone. 25G x 1 1/2 in (.50 x 38mm)...
Medicine Products: